Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients.
Splenectomy has been used in patients with common variable immunodeficiency disorders (CVID), mainly in the context of refractory autoimmune cytopenia and suspected lymphoma, but there are understandable concerns about the potential of compounding an existing immunodeficiency. With increasing use of...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797074041228492800 |
|---|---|
| author | Wong, G Goldacker, S Winterhalter, C Grimbacher, B Chapel, H Lucas, M Alecsandru, D McEwen, D Quinti, I Martini, H Milito, C Schmidt, R Ernst, D Espanol, T Vidaller, A Carbone, J Fernandez-Cruz, E Lougaris, V Plebani, A Kutukculer, N Gonzalez-Granado, L Contreras, R Kiani-Alikhan, S Ibrahim, M Litzman, J |
| author_facet | Wong, G Goldacker, S Winterhalter, C Grimbacher, B Chapel, H Lucas, M Alecsandru, D McEwen, D Quinti, I Martini, H Milito, C Schmidt, R Ernst, D Espanol, T Vidaller, A Carbone, J Fernandez-Cruz, E Lougaris, V Plebani, A Kutukculer, N Gonzalez-Granado, L Contreras, R Kiani-Alikhan, S Ibrahim, M Litzman, J |
| author_sort | Wong, G |
| collection | OXFORD |
| description | Splenectomy has been used in patients with common variable immunodeficiency disorders (CVID), mainly in the context of refractory autoimmune cytopenia and suspected lymphoma, but there are understandable concerns about the potential of compounding an existing immunodeficiency. With increasing use of rituximab as an alternative treatment for refractory autoimmune cytopenia, the role of splenectomy in CVID needs to be re-examined. This retrospective study provides the largest cohesive data set to date describing the outcome of splenectomy in 45 CVID patients in the past 40 years. Splenectomy proved to be an effective long-term treatment in 75% of CVID patients with autoimmune cytopenia, even in some cases when rituximab had failed. Splenectomy does not worsen mortality in CVID and adequate immunoglobulin replacement therapy appears to play a protective role in overwhelming post-splenectomy infections. Future trials comparing the effectiveness and safety of rituximab and splenectomy are needed to provide clearer guidance on the second-line management of autoimmune cytopenia in CVID. |
| first_indexed | 2024-03-06T23:30:37Z |
| format | Journal article |
| id | oxford-uuid:6be5c8e5-f87b-44b5-9240-92ef195faece |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:30:37Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:6be5c8e5-f87b-44b5-9240-92ef195faece2022-03-26T19:07:14ZOutcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6be5c8e5-f87b-44b5-9240-92ef195faeceEnglishSymplectic Elements at Oxford2013Wong, GGoldacker, SWinterhalter, CGrimbacher, BChapel, HLucas, MAlecsandru, DMcEwen, DQuinti, IMartini, HMilito, CSchmidt, RErnst, DEspanol, TVidaller, ACarbone, JFernandez-Cruz, ELougaris, VPlebani, AKutukculer, NGonzalez-Granado, LContreras, RKiani-Alikhan, SIbrahim, MLitzman, JSplenectomy has been used in patients with common variable immunodeficiency disorders (CVID), mainly in the context of refractory autoimmune cytopenia and suspected lymphoma, but there are understandable concerns about the potential of compounding an existing immunodeficiency. With increasing use of rituximab as an alternative treatment for refractory autoimmune cytopenia, the role of splenectomy in CVID needs to be re-examined. This retrospective study provides the largest cohesive data set to date describing the outcome of splenectomy in 45 CVID patients in the past 40 years. Splenectomy proved to be an effective long-term treatment in 75% of CVID patients with autoimmune cytopenia, even in some cases when rituximab had failed. Splenectomy does not worsen mortality in CVID and adequate immunoglobulin replacement therapy appears to play a protective role in overwhelming post-splenectomy infections. Future trials comparing the effectiveness and safety of rituximab and splenectomy are needed to provide clearer guidance on the second-line management of autoimmune cytopenia in CVID. |
| spellingShingle | Wong, G Goldacker, S Winterhalter, C Grimbacher, B Chapel, H Lucas, M Alecsandru, D McEwen, D Quinti, I Martini, H Milito, C Schmidt, R Ernst, D Espanol, T Vidaller, A Carbone, J Fernandez-Cruz, E Lougaris, V Plebani, A Kutukculer, N Gonzalez-Granado, L Contreras, R Kiani-Alikhan, S Ibrahim, M Litzman, J Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. |
| title | Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. |
| title_full | Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. |
| title_fullStr | Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. |
| title_full_unstemmed | Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. |
| title_short | Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. |
| title_sort | outcomes of splenectomy in patients with common variable immunodeficiency cvid a survey of 45 patients |
| work_keys_str_mv | AT wongg outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT goldackers outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT winterhalterc outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT grimbacherb outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT chapelh outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT lucasm outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT alecsandrud outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT mcewend outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT quintii outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT martinih outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT militoc outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT schmidtr outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT ernstd outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT espanolt outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT vidallera outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT carbonej outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT fernandezcruze outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT lougarisv outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT plebania outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT kutukculern outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT gonzalezgranadol outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT contrerasr outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT kianialikhans outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT ibrahimm outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients AT litzmanj outcomesofsplenectomyinpatientswithcommonvariableimmunodeficiencycvidasurveyof45patients |